The Conversation (0)
iCAD will present new clinical data on the use of Xoft Axxent electronic brachytherapy (eBx) system against endometrial and cervical cancer.
iCAD (NASDAQ:ICAD) announced it will present new clinical data on the use of Xoft Axxent electronic brachytherapy (eBx) system in treating endometrial and cervical cancer at the Congress of the European Society for Radiotherapy & Oncology.
As quoted in the press release:
The Company will also showcase the multi-platform Xoft System and its suite of products at its booth (#4330) throughout the meeting.
“This new clinical data analysis of endometrial and cervical cancer patients treated with the Xoft System at a European facility presents encouraging results that support the valuable benefits of this innovative treatment option,” said Ken Ferry, CEO of iCAD. “These new preliminary data add to the growing body of global research highlighting the Xoft System’s clinical value to patients and clinicians alike.”
At the meeting, researchers from Miguel Servet University Hospital in Zaragoza, Spain will present new preliminary findings on their recent clinical experience treating endometrial and cervical cancer patients with electronic brachytherapy using the Xoft System in two posters including E-poster EP-1783 entitled “Acute toxicity with Xoft Axxent Electronic Brachytherapy (XB) in endometrial or cervical cancer.”
Click here to read the full press release.
Source: globenewswire.com